SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
PhaseBio Pharmaceuticals, Inc. (PHAS) .
本页证实的标准:
- VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
SharesGrow 综合评分： 33/100 其中 0/7 项标准通过。
SharesGrow 7-Criteria Score
~
健康
50/100
Debt-to-Equity & liquidity
→ Health
估值概览 — PHAS
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率190.27
EV/EBITDA0.0
每股数据
EPS (TTM)$0.00
每股账面价值$0.00
每股营收$0.00
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2016 |
$-0.74 |
$0.00 |
$-9.22M |
- |
| 2017 |
$-0.91 |
$0.00 |
$-10.25M |
- |
| 2018 |
$-4.49 |
$668K |
$-23.85M |
-3569.8% |
| 2019 |
$-1.43 |
$2.36M |
$-39.25M |
-1662.3% |
| 2020 |
$-3.39 |
$320K |
$-98.57M |
-30801.6% |
| 2021 |
$0.00 |
$10.83K |
$-131.07K |
-1210.1% |
